Genomic Alterations Associated with Recurrence and TNBC Subtype in High-Risk Early Breast Cancers

Molecular Cancer Research : MCR
Timothy R WilsonMark R Lackner

Abstract

The identification of early breast cancer patients who may benefit from adjuvant chemotherapy has evolved to include assessment of clinicopathologic features such as tumor size and nodal status, as well as several gene-expression profiles for ER-positive, HER2-negative cancers. However, these tools do not reliably identify patients at the greatest risk of recurrence. The mutation and copy-number landscape of triple-negative breast cancer (TNBC) subtypes defined by gene expression is also largely unknown, and elucidation of this landscape may shed light on novel therapeutic opportunities. The USO01062 phase III clinical trial of standard chemotherapy (with or without capecitabine) enrolled a cohort of putatively high-risk patients based on clinical features, yet only observed a 5-year disease-free survival event rate of 11.6%. In order to uncover genomic aberrations associated with recurrence, a targeted next-generation sequencing panel was used to compare tumor specimens from patients who had a recurrence event with a matched set who did not. The somatic mutation and copy-number alteration landscapes of high-risk early breast cancer patients were characterized and alterations associated with relapse were identified. Tumor mutat...Continue Reading

References

Aug 30, 2000·Nature·C M PerouD Botstein
Jun 16, 2001·Cancer Genetics and Cytogenetics·C LathamA Zetterberg
Sep 13, 2001·Proceedings of the National Academy of Sciences of the United States of America·T SørlieA L Børresen-Dale
Feb 2, 2002·Nature·Laura J van 't VeerStephen H Friend
Dec 20, 2002·The New England Journal of Medicine·Marc J van de VijverRené Bernards
Dec 4, 2003·Cell·Luke Hughes-DaviesTony Kouzarides
Dec 29, 2005·Molecular Cancer Research : MCR·Véronique Gelsi-BoyerMax Chaffanet
Feb 11, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joel S ParkerPhilip S Bernard
Mar 12, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ana M Gonzalez-AnguloBryan T Hennessy
Aug 18, 2010·Proceedings of the National Academy of Sciences of the United States of America·Joseph H TaubeSendurai A Mani
Sep 4, 2010·Breast Cancer Research : BCR·Aleix PratCharles M Perou
Jun 3, 2011·The Journal of Clinical Investigation·Brian D LehmannJennifer A Pietenpol
Nov 10, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Benjamin D SmithThomas A Buchholz
Apr 27, 2012·Physiological Reviews·John M Kyriakis, Joseph Avruch
Jun 23, 2012·Nature·Philip J StephensMichael R Stratton
Jun 23, 2012·Nature·Shantanu BanerjiMatthew Meyerson
Aug 17, 2012·The New England Journal of Medicine·Howard I ScherUNKNOWN AFFIRM Investigators
Sep 25, 2012·Nature·UNKNOWN Cancer Genome Atlas Network
Aug 21, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Hiroko MasudaNaoto T Ueno
Sep 17, 2013·Molecular Cancer Therapeutics·Yang XiaoThomas O'Brien
Sep 12, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Matthew D BursteinPowel H Brown
Nov 5, 2014·The Journal of Clinical Investigation·Thanh U BarbieWilliam E Gillanders
Jun 5, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Joyce O'ShaughnessyStephen Jones
Jul 22, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ju-Hyun ParkMitchell H Gail
Jan 16, 2016·Cell Systems·Arthur LiberzonPablo Tamayo
Nov 7, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jeffrey R InfantePatricia M LoRusso
Dec 14, 2016·The New England Journal of Medicine·Richard S FinnDennis J Slamon
Dec 28, 2016·PLoS Medicine·Celine LefebvreFabrice André
Apr 20, 2017·Genome Medicine·Zachary R ChalmersGarrett M Frampton
Aug 25, 2017·Molecular Cancer Therapeutics·Aaron M GoodmanRazelle Kurzrock
Jan 25, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·Y BarecheC Sotiriou

❮ Previous
Next ❯

Citations

May 31, 2019·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M OliveiraS J Isakoff
Nov 4, 2020·Neoplasia : an International Journal for Oncology Research·Sebastien Taurin, Haifa Alkhalifa
Jun 10, 2021·Oncoimmunology·Annat RaiterRinat Yerushalmi
Jun 12, 2021·Head and Neck Pathology·Li LeiGerald Berry

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Sequencing

Several sequencing approaches are employed to understand and examine tumor development and progression. These include whole genome as well as RNA sequencing. Here is the latest research on cancer sequencing.

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.